Morphosys Ag Quick Ratio (MOR) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Morphosys Ag  (NASDAQ: MOR)

Morphosys Ag's Quick Ratio

MOR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2023, Quick Ratio deteriorated to 0.6 below Morphosys Ag's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 466 other companies have achieved higher Quick Ratio than Morphosys Ag in fourth quarter 2023. While Quick Ratio total ranking in the fourth quarter 2023 has deteriorated compared to the prior quarter from 1078 to 2783.

Explain Quick Ratio?
How much Cash & cash equivalents MOR´s has?
What are MOR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MOR Quick Ratio (Dec 31 2023)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2022)
Q4
Y / Y Current Liabilities Change -9.37 % -9.37 % -9.37 % -9.37 % 2.5 %
Y / Y Cash & cash equivalent Change -60.61 % -60.61 % -60.61 % -60.61 % 226.46 %
Quick Ratio MRQ 0.6 0.6 0.6 0.6 1.38
MOR's Total Ranking # 2783 # 1078 # 1093 # 1832 # 1088
Seq. Current Liabilities Change 0 % 0 % 0 % -9.37 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % -60.61 % 0 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 467
Healthcare Sector # 860
Overall Market # 2783


Quick Ratio Statistics
High Average Low
1.38 0.75 0.4
(Dec 31 2022)   (Dec 31 2020)




Financial Statements
Morphosys Ag's Current Liabilities $ 296 Millions Visit MOR's Balance sheet
Morphosys Ag's Cash & cash equivalent $ 178 Millions Visit MOR's Balance sheet
Source of MOR's Sales Visit MOR's Sales by Geography


Cumulative Morphosys Ag's Quick Ratio

MOR's Quick Ratio for the trailling 12 Months

MOR Quick Ratio

 (Dec 31 2023)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -9.37 % -6.46 % -3.51 % -0.52 % 2.5 %
Y / Y Cash & cash equivalent TTM Growth -60.61 % -34.01 % 6.71 % 76.86 % 226.46 %
Quick Ratio TTM 0.6 0.81 1.01 1.2 1.38
Total Ranking TTM # 3988 # 2033 # 1911 # 3087 # 3390
Seq. Current Liabilities TTM Growth -2.52 % -2.46 % -2.4 % -2.34 % 0.61 %
Seq. Cash & cash equivalent TTM Growth -27.78 % -21.74 % -17.86 % -15.15 % 20.98 %

Quick ratio ranking by company, industry and sector >> Back to MOR Financial Strength Comparisons >> Go to Compare MOR Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in MOR's Current Liabilities to $296.03 millions, cumulative Quick Ratio to 0.6 below the MOR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 488 other companies have achieved higher Quick Ratio than Morphosys Ag. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 2033 to 3988.

Explain Quick Ratio?
How much Cash & cash equivalents MOR´s has?
What are MOR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 489
Healthcare Sector # 992
Within the Market # 3988


trailing twelve months Quick Ratio Statistics
High Average Low
1.38 0.68 0.14
(Dec 31 2022)   0




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Galectin Therapeutics Inc   1.64 $ 25.660  Millions$ 15.676  Millions
Avalo Therapeutics Inc   1.61 $ 7.416  Millions$ 4.618  Millions
Tff Pharmaceuticals Inc  1.60 $ 5.478  Millions$ 3.432  Millions
Hyperion Defi inc   1.56 $ 14.851  Millions$ 9.530  Millions
Kiora Pharmaceuticals Inc   1.55 $ 2.455  Millions$ 1.587  Millions
Ani Pharmaceuticals Inc  1.52 $ 221.121  Millions$ 145.477  Millions
Nanobiotix S a   1.51 $ 84.317  Millions$ 55.858  Millions
Equillium Inc   1.51 $ 40.866  Millions$ 27.133  Millions
Bioage Labs Inc   1.50 $ 21.644  Millions$ 14.382  Millions
Avenue Therapeutics Inc   1.49 $ 1.783  Millions$ 1.196  Millions
Affimed N v   1.49 $ 43.152  Millions$ 29.016  Millions
Alkermes Plc   1.49 $ 773.491  Millions$ 520.220  Millions
Telix Pharmaceuticals Ltd  1.48 $ 89.532  Millions$ 60.674  Millions
Ptc Therapeutics inc   1.45 $ 876.739  Millions$ 603.100  Millions
Maia Biotechnology Inc   1.45 $ 7.151  Millions$ 4.937  Millions
Biodexa Pharmaceuticals Plc  1.44 $ 8.031  Millions$ 5.569  Millions
Procyon Corporation  1.44 $ 0.839  Millions$ 0.583  Millions
Corbus Pharmaceuticals Holdings Inc   1.44 $ 20.906  Millions$ 14.549  Millions
Apellis Pharmaceuticals Inc   1.42 $ 351.185  Millions$ 247.593  Millions
Ainos Inc   1.41 $ 1.886  Millions$ 1.337  Millions
Allarity Therapeutics Inc   1.41 $ 3.876  Millions$ 2.756  Millions
Viracta Therapeutics Inc   1.40 $ 53.691  Millions$ 38.373  Millions
Clene Inc   1.38 $ 35.000  Millions$ 25.330  Millions
Biovie Inc   1.34 $ 19.461  Millions$ 14.495  Millions
Addex Therapeutics Ltd  1.34 $ 3.865  Millions$ 2.893  Millions
Tonix Pharmaceuticals Holding Corp   1.32 $ 24.948  Millions$ 18.884  Millions
Evolus Inc   1.30 $ 62.838  Millions$ 48.291  Millions
Reviva Pharmaceuticals Holdings Inc   1.30 $ 23.367  Millions$ 17.978  Millions
Seres Therapeutics Inc   1.30 $ 127.965  Millions$ 98.659  Millions
Promis Neurosciences inc   1.29 $ 12.631  Millions$ 9.772  Millions

Date modified: 2026-09-02T20:36:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.